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A B S T R A C T
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disorder
which usually presents in the ﬁrst or second decade of life with syncope, which is typically induced by
emotional stress or exercise. We describe a large family with a history of three sudden unexpected
deaths. Investigations in the sibling of a deceased individual affected by emotion-induced syncope
revealed ventricular bigeminy. Molecular genetic testing was performed on one symptomatic individual
and a missense mutation in RYR2 was identiﬁed consistent with a diagnosis of CPVT. Subsequent cascade
testing of family members excluded 37 of 43 individuals from risk and facilitated preventative
intervention. This case highlights the value of genotyping in sudden cardiac death by deﬁning the precise
diagnosis and through the identiﬁcation and exclusion of at-risk individuals.
<Learning objective: The diagnosis of CPVT should be considered in families with a history of sudden
death in a previously asymptomatic young person. Cascade molecular genetic testing should be
undertaken as, if a pathogenic mutation is found, this can distinguish it from other arrhythmogenic
disorders and can identify at-risk individuals allowing treatment to be targeted at those in need, thus
helping to reduce the mortality associated with the condition.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Catecholaminergic polymorphic ventricular tachycardia (CPVT)
is a rare inherited arrhythmogenic disorder, which normally
presents with syncope or sudden death, typically induced by
emotional stress or exercise. It is a genetically heterogeneous
condition which is usually inherited in an autosomal dominant
pattern. Mutations in RYR2 are identiﬁed in 50–60% of cases [1]. A
rare recessive form of CPVT is due to mutations in calsequestrin 2
(CASQ2). More recently mutations in triadin (TRDN) [2] and
calmodulin 1 (CALM1) [3] have been shown to cause recessive and
dominant forms of CPVT, respectively.* Corresponding author at: Manchester Centre for Genomic Medicine, St Mary’s
Hospital, Manchester M13 9WL, UK. Tel.: +44 0161 276 6276;
fax: +44 0161 276 6145.
E-mail address: William.newman@manchester.ac.uk (W.G. Newman).
http://dx.doi.org/10.1016/j.jccase.2015.08.015
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsUnlike other inherited arrhythmogenic disorders, individuals
with CPVT usually have a normal resting electrocardiogram and
are often asymptomatic prior to a lethal event [4]. Multiple
exercise- or emotion-induced ventricular dysrhythmias may occur
and bidirectional ventricular tachycardia is pathognomonic.
The incomplete penetrance of the condition can make it difﬁcult
to identify at-risk individuals, hence molecular genetic testing can
be of particular value [5]. We describe a large family with a history
of sudden death highlighting the value and clinical utility of
molecular genetic testing for CPVT.
Clinical details
A large kindred (Fig. 1) presented after three female ﬁrst
cousins died in sudden unexpected circumstances. The individ-
uals were aged 13, 17, and 22 years (IV:12, IV:18, IV:2,
respectively). The 13-year-old collapsed and died while walking
to the shops. At post-mortem her heart was normal in size and reserved.
Fig. 1.
Pedigree of family with catecholaminergic polymorphic ventricular tachycardia. Individuals who carry the RYR2 mutation are shown in red. Those who carry the
mutation and are clinically affected are shown by a black dot in the center. Individuals who had genetic testing but were found not to carry the mutation are
shown in blue.
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having a possible seizure. While in the emergency department
she suffered a ventricular tachycardia and ventricular ﬁbrilla-
tion arrest. The post-mortem showed foci of possible myocardi-
tis with inﬁltration of histiocytes and small numbers of chronic
inﬂammatory cells. There was also evidence of pulmonary
infarction. The cause of death was recorded as possible viral
myocarditis with pulmonary infarction. The 22-year-old col-
lapsed while dancing at a party and was pronounced dead on
arrival at hospital. She had undergone a cesarean section six
weeks previously. At post-mortem the myocardium appeared
pale and ﬂabby. There was evidence of pulmonary edema, but no
emboli.
After the family was referred for genetics assessment, the
histology from all three post-mortems was reviewed. The cases
showed similar histological myocardial features (nuclear enlarge-
ment, edema between ﬁbers, and some ﬁber disruption). The
features were not consistent with a speciﬁc unifying diagnosis,
however they led to a diagnosis of hypertrophic cardiomyopathy
being considered as an explanation for the sudden deaths. The
myocardial tissue from the individuals was examined and a non-
conservative amino acid change in myosin binding protein C was
identiﬁed in two deceased individuals, but did not segregate in the
third affected individual and was therefore not considered to be
causative.
At-risk relatives were referred for cardiac assessment. All family
members had normal echocardiograms except for one individual
(V:6) where mild aortic incompetence and stenosis was seen. No
individuals displayed any evidence of hypertrophic cardiomyopa-
thy on echocardiogram.
On evaluation, several family members were symptomatic.
IV:28 was investigated for presyncopal episodes and had an
echocardiogram, exercise stress testing, and an angiogram. These
were all reported as normal.The non-identical twin sister (IV:13) of one of the individuals
described having episodes of emotionally related loss of con-
sciousness followed by palpitations. She had a normal echocar-
diogram. A 24-h electrocardiogram (ECG) revealed isolated
ectopics and couplets. Ventricular bigeminy with couplets was
recorded on an exercise stress test. The patient continued to have
syncopal episodes. She had an implantable cardioverter device
(ICD) inserted. Prior to the device insertion, right ventricular
dysrhythmias were noted and later episodes of polymorphic
ventricular tachycardia were recorded on the device electrogram
(Fig. 2). After insertion, the patient had a ventricular ﬁbrillation
(VF) arrest which was aborted by the ICD.
After obtaining written consent, Sanger sequencing for muta-
tions in genes associated with sudden cardiac death, including
KCNQ1, KCNH2, KCNE1, KCNE2, and SCN5A, was performed. No
mutations were identiﬁed in these genes. However a heterozygous
missense mutation c.1259G>A, p.(Arg420Gln) in RYR2 (Fig. 3),
which at the time had not previously been reported, was identiﬁed
consistent with a diagnosis of CPVT.
Following identiﬁcation of the mutation in RYR2, cascade
genetic testing was offered to at-risk family members. Informed
written consent was taken from individuals or the next of kin of
deceased individuals prior to undertaking genetic analysis. The
mutation was present in DNA available from autopsy tissue from
all three deceased female cousins. The RYR2 mutation has since
been independently reported as a pathogenic mutation [6] and is
not listed on the Exome Variant Server (EVS) or the Exome
Aggregation Consortium databases as a rare polymorphism. The
mutation was identiﬁed in four asymptomatic family members
(III:5, III:9, V:7 and V:8). The obligate carrier, III:2, was
asymptomatic until her 7th decade when she was admitted to
hospital with chest pain. Ventricular dysrhythmia was recorded on
treadmill testing. She was commenced on a beta-blocker. V:7 and
V:8 were asymptomatic during their childhood, however they
Fig. 2.
Biventricular polymorphic ventricular tachycardia recorded on the dual chamber implantable cardioverter device of individual IV:13. Top trace represents the
atrial channel and the bottom the ventricular. Each large square represents 0.2 s and markings on top represent 1-second intervals.
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adult and remains asymptomatic, however he has been non-
compliant with treatment and has stopped his beta-blocker
treatment. Table 1 summarizes the clinical investigations and
treatment of mutation carriers.
Importantly, testing of II:4 revealed absence of the familial RYR2
mutation. II:4 remarried after her ﬁrst husband died. She had ﬁve
children from her ﬁrst marriage and six children from her second
marriage (Fig. 1). As II:4 did not carry the mutation, her extended
family from her second marriage (totalling 20 individuals) could be
excluded from risk and symptoms being experienced by individu-
als in this branch of the family could not be attributed to the
diagnosis of CPVT. Molecular genetic testing excluded an
additional 16 at-risk family members. In total, 37 out of 43 family
members were excluded from risk.Fig. 3.
Sequence electrophoretogram of RYR2 c.1259G>A p.(Arg420Gln)
mutation in individual IV:13 (lower trace). The upper trace, which is
from a normal control, does not display this mutation.Discussion
CPVT is a rare inherited dysrhythmia characterized by episodes
of ventricular tachycardia often induced by emotional stress or
exercise. CPVT usually presents in the ﬁrst or second decade of life.
The molecular basis of CPVT is due to mutations in RYR2 in 50–60%
of affected individuals [1]. The phenotype is variable [7] and
penetrance among RYR2 mutation carriers is incomplete, estimat-
ed to be 78% [4]. In our pedigree, two obligate carriers (III:5 and
III:9) were asymptomatic at 66 and 67 years.
The majority of mutations within the RYR2 gene are missense
changes and are clustered in three functionally important
domains – the N terminal region, the central domain, and the
channel region [6]. The p.(Arg420Gln) mutation lies within the N
terminal region. Kimlicka et al. have shown that this mutation
results in the loss of chloride binding and removal of links
between two domains of RyR2, domain A and domain B [8]. This in
turn results in alterations in the domain orientations. These
alterations in domain orientations appear to be common to
mutations in both RYR1 (mutations in which can cause central
core disease, malignant hyperthermia syndrome and fetal
akinesia) and RYR2.
Many individuals are asymptomatic prior to a life-threatening
or fatal event and therefore CPVT is a condition that should always
be considered in cases of sudden death of an asymptomatic
individual. Although some individuals with RYR2 mutations may
have a slightly lower resting heart rate than individuals without
mutations, the resting ECG is usually unremarkable. Exercise tests
are often used in the diagnosis and monitoring of therapy in CPVT,
however mutation carriers may display no features during testing
[4]. As in our family, there are reports of symptomatic RYR2
mutation carriers who have inherited the pathogenic mutation
from completely asymptomatic parents [5]. Clinical assessment is
limited in the evaluation of at-risk individuals and therefore
cascade genetic testing is a more sensitive and speciﬁc way of
screening in families with CPVT. Identiﬁcation of at-risk individu-
als via molecular genetic testing means that appropriate cardiac
surveillance and treatment can be instigated to reduce the
mortality associated with the condition. Unnecessary screening
and treatment can add to the ﬁnancial burden on the healthcare
system particularly in large families. Identiﬁcation of at-risk
individuals can also help reduce anxiety within families and guide
future life decisions.
Table 1 Table summarizing the clinical features, investigations, and treatment of family members found to carry the c.1259G>A p.(Arg420Gln) mutation in RYR2.
Individual ID
on pedigree
Symptoms Age at ﬁrst
presentation if
symptomatic
Holter recording Exercise stress test Treatment
Arrhythmia Resting HR and QTc Recovery HR and QT
(immediately after exercise)
IV:2 Sudden death
(no prior symptoms)
while dancing
22 years – – – – –
IV:12 Sudden death
(no prior symptoms)
while walking
13 years – – – – –
IV:18 Possible seizure then
sudden death
(no prior symptoms)
17 years – – – – –
IV:13 Emotion related loss
of consciousness and
palpitations
24 years Isolated ectopics and couplets
(mean HR 76bpm)
Ventricular bigeminy
and couplets
HR – 60bpm
QTc – 412ms
HR – 140bpm
QTc – 460ms
Beta blockade and
ICD inserted
III:2 Chest pain 61 years Information not available Ventricular dysrhythmia Information not
available
Information not available Beta blockade
III:5 Asymptomatic at 67 years – Information not available Not undertaken – – No treatment
III:9 Asymptomatic at 68 years – Information not available Not undertaken – – No treatment
V:7 Asymptomatic at 21 years – Normal PR interval, normal QRS,
isolated couplets
Information not available Information not
available
Information not available Non-compliant with
beta blockade
treatment
V:8 Asymptomatic at 14 years – Normal PR interval, normal QRS
duration
No dysrhythmia Information not
available
Information not available Beta blockade
(Nadolol)
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In families with a history of sudden death in a previously
asymptomatic young person, the diagnosis of CPVT should be
considered. Molecular genetic testing should be pursued as, if a
pathogenic mutation is found, this can distinguish it from other
arrhythmogenic disorders and can identify at-risk individuals
allowing treatment to be targeted at those in need, thus helping to
reduce the mortality associated with the condition.
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